An ambitious UK sequencing project aims to learn more about patients with cancer and rare diseases

EMA’s pilot project continues. Is the future of regulation adaptive?

Are vaccines set for a makeover? Two studies from researchers in Massachusetts demonstrate the new approaches that R&D scientists are taking.

A group of researchers have used supercomputers to link proteins to drug side effects.

Pathways designed to bring medicines to market faster in Europe are not delivering the goods

What is an endolysin? We spoke with Bjorn Herpers from the Regional Public Health Laboratory Kennemerland, Haarlem, in the Netherlands to find out.

Could medicines be made more effective with better timing?

Will FDA fast review and voucher incentives make a difference?

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?